BPC-157 vs IGF-1

BPC-157 and IGF-1 are both research peptides studied across multiple applications, but they represent fundamentally different classes of molecules. BPC-157 is a short, synthetic peptide (15 amino acids) derived from a protective protein in human gastric juice, with a molecular weight of approximately 1419.5 g/mol. Its research focus centers on regenerative and cytoprotective effects, particularly in musculoskeletal and gastrointestinal tissues. IGF-1, in contrast, is a 70-amino acid protein hormone structurally similar to insulin, primarily produced in the liver under growth hormone stimulation. It mediates growth-promoting and metabolic effects throughout the body. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.

BPC-157 is a synthetic 15-amino-acid peptide (sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, MW ~1419.5 g/mol) derived from a protein found in human gastric juice. It has demonstrated robust regenerative and cytoprotective effects across hundreds of animal studies spanning tendon, ligament, muscle, bone, nerve, GI tract, and blood vessel healing. However, human clinical data is extremely limited — only three pilot studies have examined BPC-157 in humans as of 2025 (knee pain n=16, interstitial cystitis n=12, IV safety n=2). The FDA classifies it as Category 2, prohibiting compounding, and WADA bans its use in sports. Key claims include accelerated tendon and ligament healing, gut lining repair, and reversal of NSAID-induced GI damage, though these are primarily supported by preclinical evidence.

Insulin-like Growth Factor 1 (IGF-1) is a 70-amino acid protein structurally similar to insulin. It is primarily produced by the liver in response to growth hormone stimulation and mediates many of GH's growth-promoting effects. Recombinant human IGF-1 (mecasermin, brand name Increlex) is FDA-approved for the treatment of severe primary IGF-1 deficiency (primary IGFD) — a condition where patients have normal or elevated GH but fail to produce adequate IGF-1. IGF-1 plays critical roles in growth, development, and metabolism throughout life. It circulates bound to IGF binding proteins (primarily IGFBP-3 in a ternary complex with acid-labile subunit).

Key claims: Treats severe primary IGF-1 deficiency; Promotes muscle growth; Neuroprotective effects.

These peptides target distinct research areas with minimal overlap. BPC-157 is primarily investigated for injury recovery, including tendon, ligament, and muscle healing, as well as gut health applications such as repairing intestinal barrier integrity and treating NSAID-induced gastrointestinal damage. In contrast, IGF-1 research focuses on conditions of growth hormone axis dysfunction, such as severe primary IGF-1 deficiency, and its role in muscle growth and neuroprotection. While both peptides have been studied in wound healing contexts, their mechanisms differ significantly: BPC-157 appears to modulate angiogenesis and growth factor expression, whereas IGF-1 directly stimulates cell proliferation and differentiation via its receptor. Researchers should select based on the specific biological pathway under investigation.

BPC-157 has no completed randomized controlled human clinical trials for safety assessment. Preclinical safety studies across multiple species found no toxic or lethal dose thresholds at ranges from 6 mcg/kg to 20 mg/kg; LD1 was not achieved, and no teratogenic, genotoxic, or anaphylactic effects were observed in necropsy or histopathology. The FDA previously classified BPC-157 as Category 2 (significant safety concerns), but removed it from Category 2 on April 15, 2026. PCAC review is pending July 2026 to determine compounding eligibility. The FDA noted insufficient human safety data and potential immunogenicity risks. For IGF-1, hypoglycemia is the most common and serious adverse effect, with a black box warning on Increlex — it occurs in up to 50% of patients and must be administered with a meal to reduce risk. Injection site reactions are also common.